18F]FB-IL2 PET combined with multi-parametric MRI to analyze treatment-induced changes in tumor microenvironment in advanced cervical cancer

Completed

• Conditions: 10038594; cervical cancer

• Registration Number: NL-OMON45627
• Lead Sponsor: Afdeling Gynaecologische Oncologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

has signed informed consent
histologically confirmed advanced cervical cancer and eligible for chemoradiotherapy

Exclusion Criteria

Pre-existing auto-immune disease
The use of corticosteroids (at the start of treatment).
Contraindication for MRI (e.g. metallic foreign body, heart pacemaker, severe claustrophobia )
eGFR<60 ml/min

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The [18F]FB-IL2 uptake in tumor lesions and its relationship with the number of<br /><br>CD25+ T lymphocytes in biopsy specimens.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To assess changes in perfusion, diffusion restriction on MRI in response to<br /><br>chemoradiotherapy<br /><br>To correlate the findings between [18F]FB-IL2 PET and pathology with possible<br /><br>changes in perfusion and diffusion, as observed by multi-parameter MRI. </p><br>